Top

Published in:

Open Access 01-10-2018 | Review Article

Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies

Authors: Francis Man, Twan Lammers, Rafael T. M. de Rosales

Published in: Molecular Imaging and Biology | Issue 5/2018

Abstract

Imaging plays a key role in the preclinical evaluation of nanomedicine-based drug delivery systems and it has provided important insights into their mechanism of action and therapeutic effect. Its role in supporting the clinical development of nanomedicine products, however, has been less explored. In this review, we summarize clinical studies in which imaging has provided valuable information on the pharmacokinetics, biodistribution, and target site accumulation of nanomedicine-based drug delivery systems. Importantly, these studies provide convincing evidence on the uptake of nanomedicines in tumors, confirming that the enhanced permeability and retention (EPR) effect is a real phenomenon in patients, albeit with fairly high levels of inter- and intraindividual variability. It is gradually becoming clear that imaging is critically important to help address this high heterogeneity. In support of this notion, a decent correlation between nanomedicine uptake in tumors and antitumor efficacy has recently been obtained in two independent studies in patients, exemplifying that image-guided drug delivery can help to pave the way towards individualized and improved nanomedicine therapies.

Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–20CrossRefPubMed

Kunjachan S, Ehling J, Storm G et al (2015) Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects. Chem Rev 115:10907–10937CrossRefPubMedPubMedCentral

Chakravarty R, Hong H, Cai W (2014) Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm 11:3777–3797CrossRefPubMedPubMedCentral

Ojha T, Rizzo L, Storm G et al (2015) Image-guided drug delivery: preclinical applications and clinical translation. Expert Opin Drug Deliv 12:1203–1207CrossRefPubMed

Lammers T, Kiessling F, Hennink WE, Storm G (2010) Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 7:1899–1912CrossRefPubMed

Lanza GM, Moonen C, Baker JR et al (2014) Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology 6:1–14CrossRefPubMed

Chakravarty R, Hong H, Cai W (2015) Image-guided drug delivery with single-photon emission computed tomography: a review of literature. Curr Drug Targets 16:592–609CrossRefPubMedPubMedCentral

Prabhakar U, Maeda H, Jain RK et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412–2417CrossRefPubMedPubMedCentral

Lammers T, Rizzo LY, Storm G, Kiessling F (2012) Personalized nanomedicine. Clin Cancer Res 18:4889–4894CrossRefPubMed

10.

Natfji AA, Ravishankar D, Osborn HMI, Greco F (2017) Parameters affecting the enhanced permeability and retention effect: the need for patient selection. J Pharm Sci 106:3179–3187CrossRefPubMed

11.

Hare JI, Lammers T, Ashford MB et al (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38CrossRefPubMed

12.

Lopez-Berestein G, Kasi L, Rosenblum MG et al (1984) Clinical pharmacology of ^99mTc-labeled liposomes in patients with cancer. Cancer Res 44:375–378PubMed

13.

Turner AF, Presant CA, Proffitt RT et al (1988) In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 166:761–765CrossRefPubMed

14.

Presant CA, Proffitt RT, Turner AF et al (1988) Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer 62:905–911CrossRefPubMed

15.

Presant CA, Ksionski G, Crossley R (1990) ¹¹¹In-labeled liposomes for tumor imaging: clinical results of the International Liposome Imaging Study. J Liposome Res 1:431–436CrossRef

16.

Presant CA, Blayney D, Kennedy P et al (1990) Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet 335:1307–1309CrossRefPubMed

17.

Khalifa A, Dodds D, Rampling R et al (1997) Liposomal distribution in malignant glioma: possibilities for therapy. Nucl Med Commun 18:17–23CrossRefPubMed

18.

Stewart S, Harrington KJ (1997) The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 11:33–37

19.

Harrington KJ, Mohammadtaghi S, Uster PS et al (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243–254PubMed

20.

Koukourakis MI, Koukouraki S, Giatromanolaki A et al (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non–small-cell lung cancer and head and neck cancer. J Clin Oncol 17:3512–3521CrossRefPubMed

21.

Koukourakis MI, Koukouraki S, Giatromanolaki A et al (2000) High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy. Acta Oncol (Madr) 39:207–211CrossRef

22.

Murray JL, Kleinerman ES, Cunningham JE et al (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7:1915–1925CrossRefPubMed

23.

Giovinazzo H, Kumar P, Sheikh A et al (2016) Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmacol 77:565–573CrossRefPubMed

24.

Dams ET, Oyen WJ, Boerman OC et al (2000) ^99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 41:622–630PubMed

25.

Weers J, Metzheiser B, Taylor G et al (2009) A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 22:131–138CrossRefPubMed

26.

Farr S, Kellaway I, Parry-Jones D, Woolfrey S (1985) 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. Int J Pharm 26:303–316CrossRef

27.

Bhavna AFJ, Mittal G et al (2009) Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 71:282–291CrossRefPubMed

28.

Lee H, Shields AF, Siegel BA et al (2017) ⁶⁴Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res 23:4190–4202CrossRefPubMed

29.

Phillips E, Penate-Medina O, Zanzonico PB et al (2014) Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med 6:260ra149–260ra149CrossRefPubMedPubMedCentral

30.

Ramanathan RK, Korn RL, Raghunand N et al (2017) Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clin Cancer Res 23:3638–3648CrossRefPubMed

31.

Lyon PC, Griffiths LF, Lee J et al (2017) Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound 5:28CrossRefPubMedPubMedCentral

32.

Moek KL, Giesen D, Kok IC et al (2017) Theranostics using antibodies and antibody-related therapeutics. J Nucl Med 58:83S–90SCrossRefPubMed

33.

Petersen AL, Hansen AE, Gabizon A, Andresen TL (2012) Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev 64:1417–1435CrossRefPubMed

34.

Lamichhane N, Udayakumar T, D’Souza W et al (2018) Liposomes: clinical applications and potential for image-guided drug delivery. Molecules 23:288CrossRef

35.

James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897–965CrossRefPubMed

36.

Gregoriadis G, Swain CP, Wills EJ, Tavill AS (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 303:1313–1316CrossRef

37.

Segal AW, Gregoriadis G, Lavender JP et al (1976) Tissue and hepatic subcellular distribution of liposomes containing bleomycin after intravenous administration to patients with neoplasms. Clin Sci 51:421–425CrossRef

38.

Richardson VJ, Ryman BE, Jewkes RF et al (1979) Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer 40:35–43CrossRefPubMedPubMedCentral

39.

Perez-Soler R, Lopez-Berestein G, Kasi LP et al (1985) Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin’s disease. J Nucl Med 26:743–749PubMed

40.

Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315CrossRefPubMedPubMedCentral

41.

Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992PubMed

42.

Thakor AS, Jokerst JV, Ghanouni P et al (2016) Clinically approved nanoparticle imaging agents. J Nucl Med 57:1833–1837CrossRefPubMedPubMedCentral

43.

Heyder J (2004) Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 1:315–320CrossRefPubMed

44.

van Rijt SH, Bein T, Meiners S (2014) Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J 44:765–774CrossRefPubMed

45.

Kirpotin DB, Drummond DC, Shao Y et al (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740CrossRefPubMed

46.

Lee H, Zheng J, Gaddy D et al (2015) A gradient-loadable ⁶⁴Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine 11:155–165CrossRefPubMed

47.

Avila-Rodriguez MA, Rios C, Carrasco-Hernandez J et al (2017) Biodistribution and radiation dosimetry of [⁶⁴Cu]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res 7:98CrossRefPubMedPubMedCentral

48.

Edmonds S, Volpe A, Shmeeda H et al (2016) Exploiting the metal-chelating properties of the drug cargo for in vivo positron emission tomography imaging of liposomal nanomedicines. ACS Nano 10:10294–10307CrossRefPubMedPubMedCentral

49.

Ngoune R, Peters A, von Elverfeldt D et al (2016) Accumulating nanoparticles by EPR: a route of no return. J Control Release 238:58–70CrossRefPubMed

50.

Pérez-Medina C, Abdel-Atti D, Tang J et al (2016) Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat Commun 7:11838CrossRefPubMedPubMedCentral

51.

Daldrup-Link HE, Golovko D, Ruffell B et al (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17:5695–5704CrossRefPubMedPubMedCentral

52.

Hijnen N, Langereis S, Grüll H (2014) Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery. Adv Drug Deliv Rev 72:65–81CrossRefPubMed

53.

Wright M, Centelles M, Gedroyc W, Thanou M (2018) Image guided focused ultrasound as a new method of targeted drug delivery. In: Theranostics and image guided drug delivery. Ed.Thanou M. London: The Royal Society of Chemistry, pp 1–28

54.

Kiessling F, Fokong S, Bzyl J et al (2014) Recent advances in molecular, multimodal and theranostic ultrasound imaging. Adv Drug Deliv Rev 72:15–27CrossRefPubMed

55.

Etrych T, Lucas H, Janoušková O et al (2016) Fluorescence optical imaging in anticancer drug delivery. J Control Release 226:168–181CrossRefPubMed

56.

Negussie AH, Yarmolenko PS, Partanen A et al (2011) Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperth 27:140–155CrossRef

57.

Lamichhane N, Dewkar GK, Sundaresan G et al (2017) [18F]-Fluorinated carboplatin and [111In]-liposome for image-guided drug delivery. Int J Mol Sci 18:1079CrossRefPubMedCentral

58.

Gawne P, Man F, Fonslet J, et al. (2018) Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore. Dalt Trans 47:9283–9293

Title: Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies
Authors: Francis Man
Twan Lammers
Rafael T. M. de Rosales
Publication date: 01-10-2018
Publisher: Springer International Publishing
Published in: Molecular Imaging and Biology / Issue 5/2018
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1255-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Comparison of [99mTc]3PRGD2 Imaging and [18F]FDG PET/CT in Breast Cancer and Expression of Integrin αvβ3 in Breast Cancer Vascular Endothelial Cells

Apparent Diffusion Coefficient is a Useful Biomarker for Monitoring Adipose-Derived Mesenchymal Stem Cell Therapy of Renal Ischemic-Reperfusion Injury

Emerging Intraoperative Imaging Modalities to Improve Surgical Precision

Standardization of Small Animal Imaging—Current Status and Future Prospects

Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes

Bioluminescence Imaging for Monitoring miR-200c Expression in Breast Cancer Cells and its Effects on Epithelial-Mesenchymal Transition Progress in Living Animals